Sign inJoin waitlistJoin the waitlist

Nina Jain

Medical Director, Pediatric Diabetes Program · University of North Carolina Hospitals

Credentials: · · ·

History

Pediatric Diabetes Program · University of North Carolina Hospitals
Present
Children's Health Education Advocates · University of North Carolina Hospitals
Present
University of North Carolina Hospitals
Present

Pediatric Endocrinology
University of North Carolina Hospitals
2005–2008
Virginia Commonwealth University School of Medicine
2002–2005
Univ of Florida Coll of Med
1998–2002
University of Florida
1994–1998

Research

Mycobacterial mistranslation is necessary and sufficient for rifampicin phenotypic resistance
Proceedings of the National Academy of Sciences of the United States of America · 2014 · 153 citations
Relationship between body mass index percentile and skeletal maturation and dental development in orthodontic patients
American Journal of Orthodontics and Dentofacial Orthopedics · 2013 · 38 citations
Relating Health Locus of Control to Health Care Use, Adherence, and Transition Readiness Among Youths With Chronic Conditions, North Carolina, 2015
Preventing Chronic Disease · 2016 · 37 citations

AC
Ali Calikoglu
4 papers
MF
Maria Ferris
3 papers
Meaghan Nazareth
3 papers
Daniel Hsia
2 papers
Karina Javalkar
2 papers
Laura Hart
2 papers
Michael Freemark
2 papers · 1 as a resident
Pinar Balikcioglu
2 papers
Sarah Armstrong
2 papers · 1 as a resident
Stephen Hooper
2 papers
AP
Albert Polito
1 paper
AA
Arthur Aylsworth
1 paper

Grants

Mapping Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors
National Institute of Diabetes and Digestive and Kidney Diseases · U01
PI · $1.4M · Univ of North Carolina Chapel Hill
2024–2029

Clinical trials

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Site PI · Not yet recruiting · Phase 3
Eli Lilly and Company
2026–2032
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2027
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2024–2027